Aug 12, 2022 08:30AM
May 16, 2022 06:03AM
May 16, 2022 06:00AM
May 16, 2022 06:00AM
Apr 4, 2022 08:04AM
Apr 4, 2022 08:00AM
Mar 24, 2022 04:01PM PhaseBio Pharmaceuticals Inc. (PHAS) Reports Q4 Results, Provides Recent Business Highlights
Mar 24, 2022 04:00PM
Mar 8, 2022 08:01AM
Mar 8, 2022 08:00AM
Feb 10, 2022 08:03AM
Feb 10, 2022 08:00AM
Dec 21, 2021 08:01AM
Dec 21, 2021 08:00AM PhaseBio Provides Pemziviptadil (PB1046) Program Update
Dec 1, 2021 05:02PM
Dec 1, 2021 05:01PM
Nov 18, 2021 04:01PM
Nov 15, 2021 11:32AM
Nov 15, 2021 11:31AM
Nov 10, 2021 04:00PM
Nov 10, 2021 08:01AM PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
Nov 3, 2021 08:08AM
Nov 3, 2021 08:00AM
Oct 6, 2021 08:00AM
Sep 15, 2021 08:02AM
Sep 15, 2021 08:00AM
Aug 12, 2021 08:30AM
Aug 12, 2021 08:00AM PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antipla
Aug 10, 2021 08:02AM
Aug 10, 2021 08:00AM
Jun 17, 2021 08:06AM
Jun 17, 2021 08:00AM
May 20, 2021 04:30PM
May 17, 2021 04:35PM
May 17, 2021 04:30PM PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
May 13, 2021 04:00PM
Mar 15, 2021 08:00AM
Mar 11, 2021 08:03AM
Mar 11, 2021 08:00AM
Feb 24, 2021 04:15PM
Jan 28, 2021 08:00AM
Jan 27, 2021 04:05PM PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress
Nov 12, 2020 04:05PM
Oct 23, 2020 08:03AM
Oct 23, 2020 08:00AM
Oct 6, 2020 08:09AM
Oct 6, 2020 08:00AM
Aug 11, 2020 04:01PM
Jul 16, 2020 04:09PM PhaseBio Pharmaceuticals Inc. (PHAS) Reports First Patient Dosing in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients
Jul 16, 2020 04:05PM

322,238 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All